España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
ARS Pharmaceuticals
SPRY
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$14.71
0.63
4.47%
Pre-Market: 7:38 PM EDT
Get Report
Comment
Q3 2024 Earnings were released on Wed Nov 13th, before the market open
The most recent conference call was at 8:00 AM, 1 day ago
Click to view past webcast
ARS Pharmaceuticals (SPRY) Forecast
News
Earnings
ARS Pharmaceuticals (SPRY) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for ARS Pharmaceuticals (NASDAQ:SPRY) Stock
ARS Pharmaceuticals Stock (NASDAQ: SPRY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, November 13, 2024
ARS Pharmaceuticals shares are trading lower ...
Benzinga Newsdesk
ARS Pharmaceuticals Q3 2024 GAAP EPS $(0.20) ...
Benzinga Newsdesk
Earnings Scheduled For November 13, 2024
Benzinga Insights
Tuesday, November 12, 2024
Insights Ahead: ARS Pharmaceuticals's Quarterly Earnings
Benzinga Insights
Monday, November 11, 2024
ARS Pharmaceuticals shares are trading higher...
Benzinga Newsdesk
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024
Vandana Singh
Reported Saturday, ALK Acquires Exclusive Rig...
Benzinga Newsdesk
Thursday, October 24, 2024
ARS Pharmaceuticals Showcases Intranasal Epin...
Benzinga Newsdesk
Monday, October 14, 2024
ARS Pharmaceuticals, Inc. is on the Move, Here's Why the Trend Could be Sustainable
Zacks
Tuesday, October 08, 2024
Where ARS Pharmaceuticals Stands With Analysts
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on AR...
Benzinga Newsdesk
Monday, September 23, 2024
ARS Pharmaceuticals Announces Neffy Epinephri...
Benzinga Newsdesk
Friday, September 20, 2024
Leerink Partners Maintains Outperform on ARS ...
Benzinga Newsdesk
Monday, September 16, 2024
Cantor Fitzgerald Reiterates Overweight on AR...
Benzinga Newsdesk
Monday, September 09, 2024
ARS Pharmaceuticals Reports Submission Of sND...
Benzinga Newsdesk
Analyst Ratings For ARS Pharmaceuticals
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on AR...
Benzinga Newsdesk
Friday, September 06, 2024
ARS Pharmaceuticals, Inc. Upgraded to Buy: Here's Why
Zacks
Wednesday, September 04, 2024
ARS Pharmaceuticals Launches Pre-Ordering Ser...
Benzinga Newsdesk
Tuesday, August 27, 2024
Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned (UPDATED)
Vandana Singh
Monday, August 26, 2024
ARS Pharmaceuticals' EURneffy Adrenaline Nasa...
Benzinga Newsdesk
Wednesday, August 21, 2024
ARS Pharmaceuticals shares are trading lower ...
Benzinga Newsdesk
Tuesday, August 20, 2024
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
Vandana Singh
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
Cantor Fitzgerald Initiates Coverage On ARS P...
Benzinga Newsdesk
Monday, August 19, 2024
Looking Into ARS Pharmaceuticals's Recent Short Interest
Benzinga Insights
Tuesday, August 13, 2024
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
ARS Pharmaceuticals shares are trading higher...
Benzinga Newsdesk
Raymond James Upgrades ARS Pharmaceuticals to...
Benzinga Newsdesk
Friday, August 09, 2024
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
Vandana Singh
ARS Pharmaceuticals Says For Eligible Patient...
Benzinga Newsdesk
ARS Pharmaceuticals shares are trading higher...
Benzinga Newsdesk
FDA Approves First Nasal Spray For Treatment ...
Benzinga Newsdesk
Tuesday, August 06, 2024
ARS Pharmaceuticals Q2 EPS $(0.13) Misses $(0...
Benzinga Newsdesk
Thursday, July 25, 2024
Raymond James Initiates Coverage On ARS Pharm...
Benzinga Newsdesk
Friday, June 28, 2024
ARS Pharmaceuticals Says CHMP Of European Med...
Benzinga Newsdesk
Thursday, May 09, 2024
ARS Pharmaceuticals Q1 2024 GAAP EPS $(0.11),...
Benzinga Newsdesk
Tuesday, April 30, 2024
ARS Pharmaceuticals Submits Response For neff...
Benzinga Newsdesk
Wednesday, April 03, 2024
ARS Pharmaceuticals Submits Response To FDA C...
Benzinga Newsdesk
Thursday, March 28, 2024
Top 5 Health Care Stocks That May Plunge In March
Avi Kapoor
Tuesday, March 26, 2024
Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why
Zacks
Friday, March 22, 2024
CORRECTION: On Thursday March 21, 2024 ARS Pharmaceuticals Reported Q4 EPS $(0.07) Beats $(0.14) Estimate
Happy Mohamed
Monday, March 11, 2024
Wedbush Reiterates Outperform on ARS Pharmace...
Benzinga Newsdesk
Thursday, March 07, 2024
ARS Pharmaceuticals Reviews Recent Clinical U...
Benzinga Newsdesk
Tuesday, March 05, 2024
Leerink Partners Upgrades ARS Pharmaceuticals...
Benzinga Newsdesk
Monday, February 26, 2024
Allergic Reaction Focused ARS Pharmaceuticals' Lead Candidate Shows Efficacy In Skin Disorder
Vandana Singh
ARS Pharmaceuticals Announces neffy Meets Pri...
Benzinga Newsdesk
Tuesday, February 20, 2024
ARS Pharma Readies Data In Response To FDA's Rejection For Its EpiPen Alternative For Severe Allergic Reactions
Vandana Singh
ARS Pharma Announces Topline Results From Rep...
Benzinga Newsdesk
Monday, February 05, 2024
ARS Pharmaceuticals To Present Clinical Effic...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
